Abstract:

On the basis of the achievements in the second phase of “211” project, the Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University School of Medicine has made lots of progresses in the original priority projects such as the generation, development, early diagnosis of gastrointestinal tumors, the diagnosis and treatment of chronic liver disease. In addition, we also open up new areas in terms of the diagnosis and treatment of intestinal diseases during the third phase construction. We studied systemically the molecular mechanisms, early diagnosis and prevention of gastric cancer and colorectal cancer, especially the role of epigenetic modifications (DNA methylation, histone modification and micro RNA, etc) and signaling pathways in the development of gastrointestinal tumors. To improve the diagnostic rate, we established the key technology of capsule endoscopy and double balloon endoscopy in the diagnosis of small bowel diseases, which popularized and promoted the application of the small intestine endoscopy in our country. In addition, we explored the innovative clinical therapy and its mechanism in the refractory gastrointestinal from vascular malformation. Moreover, we established non-invasive diagnosis model to predict liver fibrosis in chronic hepatitis B, and clarified the role and the mechanism of the nucleoside antivirals and oxymatrine in the inhibition of fibrosis and prevention its progress. Through the 5-year efforts, we have got two National Science and Technology Progress Awards, and have become the key national clinical specialist (Department of Gastroenterology) and the key national clinical specialist (Key Laboratory of Ministry of Health). The overall level of our discipline has been markedly improved.

Key words: gastrointestinal tumor, small intestine diseases, chronic liver disease, Department of Gastroenterology, Renji Hospital